{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T03:20:02Z","timestamp":1779333602528,"version":"3.51.4"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2001,6,26]]},"abstract":"<jats:p>\n            <jats:italic>Background<\/jats:italic>\n            \u2014Patients with a non\u2013ST-elevation acute coronary syndrome and prior CABG are at high risk of a recurrent ischemic event despite aspirin therapy. This trial investigated the potential benefit of secondary prevention with warfarin.\n          <\/jats:p>\n          <jats:p>\n            <jats:italic>Methods and Results<\/jats:italic>\n            \u2014In a double-blind randomized trial, 135 patients with unstable angina or non\u2013ST-segment elevation myocardial infarction, with prior CABG, and who were poor candidates for a revascularization procedure received therapy with aspirin and placebo+warfarin, warfarin and placebo+aspirin, or aspirin and warfarin for 12 months. Warfarin was titrated to an international normalized ratio of 2.0 to 2.5. The primary end point (death or myocardial infarction or unstable angina requiring hospitalization 1 year after randomization) occurred in 14.6% of the patients in the warfarin-alone group, in 11.5% of patients in the aspirin-alone group, and in 11.3% of patients randomized to the combination therapy (\n            <jats:italic>P<\/jats:italic>\n            =0.76). Subgroup analyses by risk features provided no indications that warfarin alone or in combination with aspirin could be of benefit over aspirin alone. Bleeding was more frequent in the 2 groups of patients administered warfarin.\n          <\/jats:p>\n          <jats:p>\n            <jats:italic>Conclusions<\/jats:italic>\n            \u2014Moderate-intensity oral anticoagulation alone or combined with low-dose aspirin does not appear to be superior to low-dose aspirin in the prevention of recurrent ischemic events in patients with non\u2013ST-elevation acute coronary syndromes and previous CABG.\n          <\/jats:p>","DOI":"10.1161\/01.cir.103.25.3069","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:09:32Z","timestamp":1339459772000},"page":"3069-3074","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":41,"title":["Aspirin, Warfarin, or the Combination for Secondary Prevention of Coronary Events in Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Surgery"],"prefix":"10.1161","volume":"103","author":[{"given":"Thao","family":"Huynh","sequence":"first","affiliation":[{"name":"From the Montreal General Hospital (T.H., S.S.), the Montreal Heart Institute (P.T.), and Sacre\u0301-Coeur Hospital (J.N.), Montreal, Quebec, and the Quebec Heart Institute (P.B.), Quebec, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"The\u0301roux","sequence":"additional","affiliation":[{"name":"From the Montreal General Hospital (T.H., S.S.), the Montreal Heart Institute (P.T.), and Sacre\u0301-Coeur Hospital (J.N.), Montreal, Quebec, and the Quebec Heart Institute (P.B.), Quebec, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bogaty","sequence":"additional","affiliation":[{"name":"From the Montreal General Hospital (T.H., S.S.), the Montreal Heart Institute (P.T.), and Sacre\u0301-Coeur Hospital (J.N.), Montreal, Quebec, and the Quebec Heart Institute (P.B.), Quebec, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Nasmith","sequence":"additional","affiliation":[{"name":"From the Montreal General Hospital (T.H., S.S.), the Montreal Heart Institute (P.T.), and Sacre\u0301-Coeur Hospital (J.N.), Montreal, Quebec, and the Quebec Heart Institute (P.B.), Quebec, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Solymoss","sequence":"additional","affiliation":[{"name":"From the Montreal General Hospital (T.H., S.S.), the Montreal Heart Institute (P.T.), and Sacre\u0301-Coeur Hospital (J.N.), Montreal, Quebec, and the Quebec Heart Institute (P.B.), Quebec, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","first-page":"87","volume":"5","year":"1989","unstructured":"Lambert M, Kouz S, Campeau L. Preoperative and operative predictive variables of late clinical events following saphenous vein coronary artery bypass graft surgery. Can J Cardiol. 1989;5:87\u201392.","journal-title":"Can J Cardiol"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(86)90016-0"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(88)90447-0"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)89383-6"},{"key":"e_1_3_2_5_2","first-page":"73","volume":"307","year":"1984","unstructured":"Chesebro JH, Clements IP, Fuster V, et al. A platelet-inhibitor drug trial in coronary artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med. 1984;307:73\u201378.","journal-title":"N Engl J Med"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198401263100401"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(19)38592-7"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.84.2.1860197"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.72.1.3874009"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90253-5"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91815-4"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(90)90535-9"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.1986.tb07927.x"},{"key":"e_1_3_2_14_2","first-page":"493","volume":"28","year":"1996","unstructured":"Chen L, Theroux P, Lesperance J, et al. Angiographic features of vein grafts versus ungrafted coronary arteries in patients with unstable angina and previous bypass surgery. J Am Coll Cardiol. 1996;28:493\u2013499.","journal-title":"J Am Coll Cardiol"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(93)90243-T"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(98)70196-6"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11475-1"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701163360301"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)01180-X"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.102.2.157"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(98)00378-7"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.89.1.8281698"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.98.11.1064"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)01118-9"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/000331979905000901"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","unstructured":"Kauhanen P Siren V Carpen O et al. Plasminogen activator inhibitor-1 in neointima of vein grafts: its role in reduced fibrinolytic potential and graft failure. Circulation. 1997;96;1783\u20131789.","DOI":"10.1161\/01.CIR.96.6.1783"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI7141"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02324-2"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)07350-X"},{"key":"e_1_3_2_30_2","unstructured":"Yusuf S. Clopidogrel in the Unstable Angina to Prevent Recurrent ischemic Events (CURE). Presented at: Scientific Sessions American College of Cardiology; March 18\u201321 2001; Orlando Fla."}],"updated-by":[{"DOI":"10.1161\/01.cir.0000155489.11621.70","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2005,1,25]],"date-time":"2005-01-25T00:00:00Z","timestamp":1106611200000}}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.CIR.103.25.3069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T13:19:34Z","timestamp":1715519974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.CIR.103.25.3069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6,26]]},"references-count":30,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2001,6,26]]}},"alternative-id":["10.1161\/01.CIR.103.25.3069"],"URL":"https:\/\/doi.org\/10.1161\/01.cir.103.25.3069","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6,26]]},"assertion":[{"value":"2000-10-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-04-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-06-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}